The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Substitution of cisplatin for etoposide in 2 of 3 induction cycles of CAV/IE with subsequent irinotecan and vincristine for relapse in adults with Ewing sarcoma (ES) and primitive neuroectodermal tumor (PNET).
Daniel A. Rushing
No relevant relationships to disclose
Obiageli Ezewuiro
No relevant relationships to disclose
Sandra S. Staehler
No relevant relationships to disclose
Kristin Potter
No relevant relationships to disclose
Luis Rojas
No relevant relationships to disclose
Stephanie Glacy Wagner
No relevant relationships to disclose